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Abstract
Background: Malignant mesothelioma (MM) is an aggressive tumor that is resistant to conventional modes of
treatment with chemotherapy, surgery or radiation. Research into the molecular pathways involved in the
development of MM should yield information that will guide therapeutic decisions. Epidermal growth factor
receptor (EGFR) and cyclooxygenase-2 (COX-2) are involved in the carcinogenesis of MM. Combination of COX-2
and EGFR inhibitors, therefore, could be an effective strategy for reducing cell growth in those lines expressing the
two molecular markers.
Results: In order to verify the effect of COX-2 and EGFR inhibitors, five MM cell lines NCI-2452, MPP89, Ist-Mes-1,
Ist-Mes-2 and MSTO-211 were characterized for COX-2 and EGFR and then treated with respective inhibitors
(rofecoxib and gefitinib) alone and in combination. Only MPP89, Ist-Mes-1 and Ist-Mes-2 were sensitive to rofecoxib
and showed growth-inhibition upon gefitinib treatment. The combination of two drugs demonstrated synergistic
effects on cell killing only in Ist-Mes-2, the cell line that was more sensitive to gefitinib and rofecoxib alone. Down-
regulation of COX-2, EGFR, p-EGFR and up-regulation of p21 and p27 were found in Ist-Mes-2, after treatment with
single agents and in combination. In contrast, association of two drugs resulted in antagonistic effect in Ist-Mes-1
and MPP89. In these cell lines after rofecoxib exposition, only an evident reduction of p-AKT was observed. No
change in p-AKT in Ist-Mes-1 and MPP89 was observed after treatment with gefitinib alone and in combination
with rofecoxib.
Conclusions: Gefitinib and rofecoxib exert cell type-specific effects that vary between different MM cells. Total
EGFR expression and downstream signalling does not correlate with gefitinib sensitivity. These data suggest that
the effect of gefitinib can be potentiated by rofecoxib in MM cell lines where AKT is not activated.
Background
Malignant mesothelioma (MM) is a fatal malignancy
with an estimated incidence of 3,000 cases per year in
the United States. In the next 30 years in Western Eur-
ope, 250,000 deaths are envisaged [1]. There is no stan-
dard of care for MM, and current treatments, ranging
from aggressive surgical treatment to chemotherapy, fail
to improve the disease prognosis [2]. MM occurs in a
context of asbestos exposure and chronic inflammation,
such as would be expected to enhance the expression of
inducible enzymes which cyclooxygenase (COX). Two
COX isoforms have been identified as COX-1 and
COX-2 [3]. COX-1 is expressed constitutively in several
cell types of normal mammalian tissues, where it is
involved in the maintenance of tissue homeostasis. In
contrast, COX-2 is an inducible enzyme responsible for
prostaglandin-E2 (PGE2) production at sites of inflam-
mation [3]. Cyclooxygenase activity occurs in cultured
human MM cells and COX-2 is induced by inflamma-
tory cytokines [4]. Nevertheless, COX-2 expression is a
strong prognostic factor in human MM, which contri-
butes independently of the other clinical and histopatho-
logical factors in determining a short survival [5].
Several studies have shown that non-steroidal anti-
inflammatory drugs (NSAID) are able to prevent the
development of various human cancers, including MM
[6-8], even if the exact molecular mechanisms in
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chemoprevention of NSAID are not clearly understood.
There is good correlation between high levels of COX-2
and tumour cell sensitivity to NSAIDs [9]. As a result,
COX-2 has become a natural target for anti-cancer agents
[10] and selective COX-2 inhibitors, such as celecoxib and
rofecoxib, have been considered for therapy [11,12]. The
induction of COX-2 and up-regulation of the prostaglan-
din cascade play a significant role in carcinogenesis by
promoting cell division [13], induction of vascular
endothelial growth factor and stimulation of an antiapop-
totic pathway [14]. In turn, COX 2 may be additionally
up-regulated as a positive feedback mechanism by EGFR
pathway [15]. EGFR, a receptor tyrosine kinase , is over-
expressed in a wide variety of epithelial malignancies
including MM [16]. It is known that 68% of MM speci-
mens show EGFR expression [17]. In rat pleural MM cells,
the phosphorylation of EGFR appears to correlate with the
carcinogenicity of the asbestos fibers, with a greater degree
of phosphorylation observed after treatment with fibrous
preparations [18]. Asbestos fibers also induced the phos-
phorylation of mitogen-activated protein kinase and extra-
cellular signal-regulated kinase (ERK) 1 and 2 [19]. EGFR
appears to be involved in the constitutive activation of the
phosphoinositide-3-kinase (PI3/AKT) signalling pathway
in MM cell lines and other solid tumors as well as in their
resistance to treatment, such as radiation and chemiother-
apy [20]. Phosphorylated AKT conveys downstream sig-
nals, promoting cellular proliferation and survival [21].
Several strategies have been developed for targeting
EGFR, including low molecular weight tyrosine kinase
inhibitors [22]. Gefitinib (Iressa, ZD-1839) acts as a
competitive inhibitor of ATP for binding to the EGFR
tyrosine kinase pocket [23] and inducing the formation
of inactive EGFR dimers and homodimers [24]. EGFR
inhibitors have been shown to be effective in preclinical
studies and animal models and are in the final stages of
clinical trials [25]. Besides, the interaction between the
EGFR and COX-2 pathways [26,15] could suggest that
targeting both EGFR and COX-2 may be an effective
approach to modulate both pathways and their down-
stream signalling, which may result in an increased ther-
apeutic response in MM.
The combination of COX-2 and EGFR inhibitor was
shown to have a synergistic effect in cancer treatments
[27]. Combined treatment with a COX-2 inhibitor and
an EGFR-TKI has been shown to inhibit the EGFR-
mediated pathways, including ERK and AKT [28]. Based
on the relevance of the COX-2 and EGFR pathways in
MM [4,5,17,18] and the overlap between the two path-
ways [15], we performed studies to characterize five
MM cell lines for COX and EGFR signalling and to ana-
lyze their response to COX-2 and EGFR inhibitors as
single agent or in combination.
Methods
Cell Lines
The human MM cell lines MSTO-211H and NCI-
H2452 were obtained from the American Type Culture
Collection (Rockville, MD). Cells were cultured as
monolayers in flasks using ATCC complete growth
medium in a humidified atmosphere containing 5% CO2
at 37°C. The human MM cell lines Ist-Mes-1, Ist-Mes-2
and MPP89 were obtained from the Genova Institute
Culture Collection. Ist-Mes-1 and Ist-Mes-2 were cul-
tured in Dulbecco’s modified eagle medium (DMEM)
with piruvate, supplemented with 10% FBS, glutamine (2
mM), 1% non essential aminoacids and antibiotics (0.02
IU.mL/1 penicillin and 0.02 mg.mL/1 streptomycin)
while the established MM cell line, MPP89, was main-
tained in Ham’s F10 with 15% FBS, and supplemented
with glutamine (2 mM) and antibiotics (0.02 IU.mL/1
penicillin and 0.02 mg.mL/1 streptomycin) in a humidi-
fied atmosphere containing 5% CO2 at 37°C.
Drugs
Gefitinib and rofecoxib (Sequoia Research Product, UK)
stock solutions were prepared in DMSO and stored at
-20°C. The drugs were diluted in fresh media before
each experiment. EGF was purchased from Biosource
International Inc. (Camarillo, CA), dissolved in distilled
H2O and stored at -70°C before use.
Protein Extraction and Western Blot Analysis
MM cells were used to determine the baseline expres-
sion of the COXs, EGFR and EGFR phosphorylation.
Ist-Mes-1, Ist-Mes-2 and MPP89 were treated with EGF
to increase the level of EGFR phosphorylation. Cells
were seeded in full culture media for 24 h before 100
ng/ml of EGF was added for 15 and 30 min. MM cells
were lysed in ice-cold lysis buffer (20 mM Tris (pH 8.0),
150 mM NaCl, 10% glycerol, 1% NP40, and 0.42% NaF)
containing proteinase and phosphatase inhibitors (Pierce
Biotechnology) and separated on SDS-PAGE. The sepa-
rated proteins were transferred onto nitrocellulose
membranes, blocked with 5% milk, and incubated over-
night at 4°C with antibodies against the phosphorylated
proteins. After 1 h incubation with the horseradish per-
oxidase-conjugated secondary antibody, the phosphory-
lated proteins were revealed by ECL Western blotting
detection reagents (Amersham Pharmacia; Uppsala,
Sweden) according to the manufacturer’s instructions.
Membranes were stripped by incubation in 1 M Tris-
HCl (pH 6.8), 10% SDS, and 10 mM dithiotreitol for 30
min at 55°C, and re-probed with antibodies of interest.
Goat anti mouse or rabbit IgG horseradish peroxidase-
conjugated secondary antibodies (1:3,000) (Bio-Rad
Laboratories; Hercules, CA, USA) was used. The blots
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were then reacted with ECL Western blotting detection
reagents and intensity assessed by densitometric analysis
of digitalized autoradiographic images using Scion
Image software. Actin was used as a loading control.
The experiments were performed in triplicate. Proteins
were probed with antibodies against COX-2 (monoclo-
nal antibody Cayman Chemical (1:500) , EGFR-1005
(1:1,000) and phospho-specific EGFR p-Tyr-PY20
(1:100), p27 and p21 (1:250) (S. Cruz Biotechnology,
Santa Cruz, CA, USA), AKT (1:1,000), pAKT (1:1,000),
ERK1/2 (1:1,000) and pERK1/2 (1:1,000) (Cell Signaling
Technology) and monoclonal anti actin (1:10,000)
(Sigma, Saint Louis Missouri, USA).
RNA isolation and RT-PCR
Total RNA was prepared from cultured MSTO-211H,
NCI-H2452, Ist-Mes-1, Ist-Mes-2 and MPP89 using
TRIzol Reagent (Invitrogen Life Technologies, Paisley,
UK) according to the manufacturer’s protocols. Reverse
transcription of RNA, for first-strand cDNA synthesis,
was performed using 4 μg total RNA and 0.5 μg oligo
(dT) 12-18 primer (Invitrogen Life Technologies, Paisley,
UK), 10 mM dNTP mix in a final volume of 12 μl. The
reaction was incubated at 70°C for 10 min and immedi-
ately chilled on ice. Primer extension was then per-
formed for 10 mins at room temperature and 42°C for 2
mins following addition of First -Strand Buffer, 10 mM
dithiothreitol, and 40U RNase OUT Recombinant Ribo-
nuclease Inhibitor (Invitrogen Life Technologies, Paisley,
UK) in a final volume of 19 μl. 1 μl (200U) SuperScript
II Reverse Transcriptase was then added (Invitrogen Life
Technologies, Paisley, UK) and incubated at 42°C for 50
min. The reaction was inactivated by heating at 70°C
for10 mins. cDNA was stored at -20°C.
Quantitative PCR was conducted in a volume of 25 μl
containing 40 ng cDNA (1/100 dilution of reverse tran-
scriptase mixture), 1.25 μl of primer (COX-2 or EGFR)
and 12.5 μl TaqMan Universal PCR Master Mix
(Applied Biosystems, Foster City, CA, USA) in the fol-
lowing sequence: 2 mins at 50°C and denaturation for
10 mins at 95°C followed by 40 cycles of the amplifica-
tion step at 95° for 15 secs (denaturation), and then at
60°C for 60 secs (annealing/extension) in 96-well plates
using the ABI PRISM 7000 sequence Detection System
(Applied Biosystems, Foster City, CA, USA). Quantita-
tive PCR for the endogenous control glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was carried out
under the same conditions, using a GAPDH Assay on
Demand (Applied Biosystems, Foster City, CA, USA). A
standard curve for COX-2 and EGFR genes was con-
structed using serial dilutions (200-40-8-1.6 ng) from a
pool of cDNAs from MSTO, NCI, Ist-Mes-1, Ist-Mes-2
and MPP89 cells. Results were analyzed using the
Applied Biosystems analysis software and expression
levels calculated from a linear regression of the standard
curve. Results are given as gene expression vs GAPDH
expression (COX-2 or EGFR relative expression) to cor-
rect for differences in the quantity of cDNA used in the
PCR reaction. All quantitative PCR reactions for each
sample were performed in triplicate.
In Vitro Cytotoxicity Assays
The in vitro drug sensitivity was assessed by Cell Prolif-
eration kit (XTT) (Roche Molecular Biochemicals, India-
napolis, IN), using the manufacturer’s instructions. The
assay is based on the cleavage of the yellow tetrazolium
salt XTT to form an orange formazan dye by metabolic
active cells. This conversion only occurs in viable cells.
The formazan dye formed is soluble in aqueous solu-
tions and is directly quantified using a scanning multi-
well spectrophotometer at 492 nm with a reference
wavelength at 650 nm. Cells were seeded at 2,500-
20,000 cells/well in 96-well flat-bottomed plate (Corning
Inc., Corning, NY) to allow for an exponential growth
for the 3 days of the assay to give an absorbance of 1.0-
2.2. The optimum number of cells required to reach an
absorbance between 1.0 and 2.2 was determined for
each cell line (data not shown). In a typical experiment,
cells were trypsinized, seeded in 96-well plates, and
allowed to recover for 24 h before the addition of gefiti-
nib or rofecoxib or gefitinib and rofecoxib together.
Drug concentrations ranged from 6.25 μM to 50 μM for
gefitinib, 4 μM to 36 μM for rofecoxib. The concentra-
tion of drugs required to obtain a 25% inhibition (IC25)
of proliferation of Ist-Mes-2, was used to test the effec-
tiveness of the rofecoxib and gefitinib association in
each cell line. To 25 μM gefitinib (Ist-Mes-2 IC25) were
added 4, 12 and 36 μM of rofecoxib and to 12 μM rofe-
coxib was added 12, 5 μM gefitinib. All experimental
points were quantified fivefold. Every single point was
compared to their respective control with the same
amount of DMSO. All experiments were repeated three
times. The assay was developed after 48 h incubation
and absorbance was then measured. The cytotoxic effect
obtained with the gefitinib and rofecoxib combinations
was analysed according to the Chou and Talalay method
[29]. Combination index (CI) values above 1.1 indicate
antagonistic, 0.9 to 1.1 additive, 0.7 to 0.9 moderately
synergistic, 0.3 to 0.7 synergistic, and <0.3 strongly
synergistic.
Drug treatment
The anti-proliferative activity of single drug treatments
was assessed in a monolayer culture condition by plating
Ist-Mes-1, Ist-Mes-2 and MPP89 cells in T25 flask.
After 24 h, DMSO (at the same final concentration of
that present in medium with drugs), 50 μM gefitinib or
36 μM rofecoxib were added. The cells were then
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harvested at 48 h after treatment and analyzed by wes-
tern blot and RT-PCR to evaluate the effect of the drugs
on expression and mRNA levels of EGFR and COX-2.
The expression of the cell cycle arrest genes and p-
AKT, AKT, p-ERK and ERK was detected by Western
blot (as described above) to assess the antiproliferative
activity of the two drugs in isolation (25 μM gefitinib or
4 μM rofecoxib) and in combination 25 μM gefitinib+4
μM rofecoxib.
Treatment of MM cells with Gefitinib and EGF
To determine the effect of gefitinib on the phosphoryla-
tion status of EGFR, Ist-Mes-1, Ist-Mes-2 and MPP89,
cells were seeded in T25 flask in full culture media for
24 h. 45 mins after the addition of gefitinib, EGF (final
concentration 100 ng/ml) was added. DMSO was added
to the control medium to give a final concentration that
matched DMSO present in medium containing drugs.
The cells were harvested 1 h after gefitinib addition,
lysed and analyzed by RT-PCR and Western blot as
described above. Cells treated with EGF for 15 mins
were used to control for EGF-induced phosphorylation.
Statistical Analysis
Comparisons of treatment outcomes were tested for sta-
tistical differences using the Student t-test for paired
data. Statistical significance was assumed at a P-value of
≤ 0.05.
Results
Effect of rofecoxib on the viability of MM cells
Cell growth of MM cell lines treated with rofecoxib, of
doses ranging from 4 to 36 μM, was determined by
the cell proliferation kit. Figure 1A shows the effect of
rofecoxib on the survival of the five MM cell lines.
The largest dose of drug caused a cell proliferation of
68% in MPP89, of 58% in Ist-Mes-1 and 40% in Ist-
Mes-2. MSTO-211H and NCI-H2452 treated with 36
μM of rofecoxib had a survival of 97% and 90%
respectively, when compared with their controls. The
concentration of drug required to obtain a 50% inhibi-
tion of proliferation in vitro (IC50) was determined
only in the cell lines most sensitive to the drugs (Fig-
ure 1D). In detail, IC50 was obtained by extrapolation
from the cytotoxicity curve. Despite the fact that
extrapolation may not be the best method with which
to calculate the IC50, it provided us with an indication
of the different sensitivity of cell lines. In the same
cell lines the effect of rofecoxib on COX-2 was also
tested. Ist-Mes-1, Ist-Mes-2 and MPP89 cell lines
incubated with 36 μM rofecoxib for 48 h showed a
significant decrease in both COX-2 and mRNA levels
(Figure 1B and 1C), indicating a specific effect of rofe-
coxib on COX2.
EGFR signalling in MM cells
Basal level of EGFR transcript was detected by RT-PCR
and Western blot in MPP89, Ist-Mes-2 and Ist-Mes-1
cell lines, at a lower level in MPP89 (Figure 2A and 2B).
Different levels of EGFR phosphorylation (P-EGFR)
were detected in the cell lines analyzed (Figure 2B). In
Ist-Mes-1, Ist-Mes-2 and MPP89 cell lines, the addition
of EGF at a concentration of 100 ng/mL significantly
increased EGFR phosphorylation after 15 mins, when
compared with the control. (Figure 2C). Exogenous EGF
trigged a further increase in ERK and AKT phosphoryla-
tion in MPP89 and AKT phosphorylation in Ist-Mes-1,
indicating that the EGF-EGFR pathway was activated in
these cell lines. Interestingly, in Ist-Mes-2 cells, EGF sti-
mulation induced EGFR phosphorylation as expected,
but did not induce AKT and ERK phosphorylation, sug-
gesting other possible signalling pathways of EGFR.
Effect of gefitinib on the viability of MM cells
Cell growth of MPP89, Ist-Mes-1, Ist-Mes-2 cells treated
with gefitinib at doses ranging from 6.25 to 50 μM, was
determined by the cell proliferation kit. In MPP89, Ist-
Mes-1 and especially in Ist-Mes-2, a significant growth
inhibition by gefitinib was observed (Figure 3A). In fig-
ure 3D the IC50 demonstrates the greater drug sensitiv-
ity in Ist-Mes-2 than in Ist-Mes-1 and MPP89. In Ist-
Mes-1 and MPP89 cell lines, upon gefitinib treatment,
only a mild decrease in the EGFR mRNA level was
observed (Figure 3C). In Ist-Mes-2 cell, gefitinib treat-
ment resulted in a significant decrease in EGFR protein
(Figure 3B), as well as mRNA level (Figure 3C). Signifi-
cant inhibition of phosphorylation of the EGFR was
observed with gefitinib (50 μM) in the EGF-treated Ist-
Mes-2 (Figure 3E). AKT phosphorylated was not
detected in this cell line upon EGF treatment. However,
exogenous EGF triggered further increases in EGFR and
AKT phosphorylation in the Ist-Mes-1 and MPP89 cells
that were reversed by gefitinib (Figure 3E).
Effect of gefitinib and rofecoxib combination on the
viability of MM cells
Cell growth of Ist-Mes-1, Ist-Mes-2 and MPP89 cells
treated with four combinations of gefitinib-rofecoxib
was determined by the cell proliferation kit. The con-
centration of drugs required to obtain a 25% inhibition
(IC25) of proliferation in vitro, was used to test the effec-
tiveness of the rofecoxib and gefitinib association in
each of the cell lines. A beneficial effect of a simulta-
neous use of both drugs was not observed in Ist-Mes-1
and MPP89 cell lines (data not shown). The exposure to
the two drugs induced an effect which was less severe
than would be expected from the sum of the effects that
each drug would produce on its own. One drug, there-
fore, counteracted some of the effects of the other. To
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Figure 1 Curves of cell proliferation and COX-2 modulation after addition of rofecoxib at various concentrations in the MM cell lines.
A, the graphs represent cell growth curves of the five cell lines treated with 4, 12, and 36 μM of drug (Rofecoxib) compared to cells treated
with DMSO at the same final concentration of that present in medium with drugs (CNTRL) as described in material and methods. The survival of
cells was expressed as absorbance (A 492 nm-A690 nm) and % of proliferation (on the right bottom). To evaluate the modulation of rofecoxib on
COX-2, Ist-Mes-1, Ist-Mes-2 and MPP89 cell lines were treated with 36 μM rofecoxib for 48 h. The effect of the drug was evaluated by Western
blot (B) and quantitative PCR (C). The table (D) displays IC50 in the cell lines more sensitive to rofecoxib.
Figure 2 Characterization of EGFR in the MM cell lines. Levels of mRNA were revealed by quantitative PCR (A), EGFR RNA quantity indicates
EGFR gene expression vs GAPDH. The standard deviation expresses the result of three different quantizations and expression of EGFR protein
was revealed by quantitative PCR. The western blot (B) shows the levels of EGFR and phosphorylated EGFR protein (P-EGFR) in MM cell lines. Cell
extracts (100 μg) were probed for phospho-specific EGFR p-Tyr-PY20 and detected with ECL. Blots were stripped and then re-probed for EGFR.
Actin was used as loading control. C, effect of EGF on phosphorylation of EGFR, AKT and ERK. The cells were cultured in complete medium for
24 and then treated with EGF (100 ng/mL) for 15 and 30 min. Western blot of total lysates (60 μg) indicates that the addition of EGF at a
concentration of 100 ng/mL significantly increased EGFR phosphorylation already after 15 minutes. AKT also become phosphorylated in Ist-Mes-1
and MPP89, whereas ERK become phosphorylated in MPP89.
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verify whether this effect was reversed by a lower con-
centration of drugs, the concentrations of drugs tested
on Ist-Mes-2 were also used in Ist-Mes-1 and MPP89.
The dosage used for the cell lines was 25 μM of gefiti-
nib with increasing doses of rofecoxib (4, 12 and 36
μM) and 12 μM rofecoxib with 25 μM gefitinib (Figure
4). None of the combinations produced any significant
inhibition of cell proliferation with respect to the single
drugs, except in Ist-Mes-2, where a synergistic effect of
the two drugs was detected (Table 1). In particular, con-
centration of 12 μM rofecoxib+25 μM gefitinib led to a
significant decrease in cell proliferation (21%) compared
to 12 μM rofecoxib (45%) and 25 μM gefitinib (45%)
alone (Figure 4). Otherwise, treatments with 25 μM gefi-
tinib+4 μM rofecoxib and 25 μM gefitinib+36 μM rofe-
coxib caused a reduction of 25% and 19% respectively,
compared to treatments with single drugs (45% for 25
μM gefitinib, 95% for 4 μM rofecoxib and 36% for 36
μM rofecoxib).
Effect of Rofecoxib and Gefitinib on p27, p21 and p-AKT
expression
To determine the biochemical mechanisms of drug-
induced growth inhibition in MM, we evaluated the
effect of gefitinib and rofecoxib on cell cycle inhibitors
p21 and p27. According to the results obtained,
Figure 3 Curves of cell proliferation and EGFR modulation after addition of gefitinib at various concentrations. A, the graphs represent
cell growth curves of the Ist-Mes-1, Ist-Mes-2 and MPP89 cell lines treated with 6.25, 12.5, 25 and 50 μM of drug (Gefitinib) compared to cells
treated with DMSO at the same final concentration of that present in medium with drugs (CNTRL) as described in material and methods. The
survival of cells was expressed as absorbance (A 492 nm-A690 nm) and % of proliferation (on the right bottom). To evaluate the modulation of
gefitinib on EGFR, Ist-Mes-1, Ist-Mes-2 and MPP89 cell lines were treated with 50 μM gefitinib for 48 h. The effect of the drug was evaluated by
western blot (B) and quantitative PCR (C). The table (D) displays gefitinib IC50 in the cell lines. E, effect of gefitinib on EGFR and AKT
phosphorylation. Ist-Mes-1, Ist-Mes-2 and MPP89 cells were cultured in complete medium for 24 hours and then treated with gefitinib 50 μM as
described in materials and methods. EGFR-phosphorylation (P-EGFR) and AKT-phosphorylation (P-AKT) were analyzed by western blot as
described above. Cell treated with EGF were used to control for EGF-induced phosphorylation. DMSO was added to the medium of control to
give a final concentration that matched DMSO present in medium containing drugs.
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illustrated in Figure 2, 4 and 5, we observed expression
of p21 and p27 proteins only in Ist-Mes-2 cells (Figure
5). Indeed, in this cell line, treatment with single agent
or rofecoxib and gefitinib as combination induced a sig-
nificant increase of p21 and p27. Interestingly, in Ist-
Mes-1 and MPP89 no differences in p21 and p27 were
observed, when compared to control (Figure 5). Rofe-
coxib strongly inhibited constitutive p-AKT in Ist-Mes-1
and MPP89. Of note, gefitinib had no effect on baseline
p-AKT in the Ist-Mes-1 and MPP89. In both cell lines
MPP89 and Ist-Mes-1, association of the two drugs did
not act on p-AKT, confirming an antagonistic effect of
gefitinib in combination with rofecoxib. There was no
detectable p-AKT despite abundant expression of AKT
in Ist-Mes-2 cells. It is possible that in this cell line the
AKT pathway may not be active, compared to Ist-Mes-1
and MPP89. Together, these data suggest that the
response of MM cell lines upon gefitinib treatment is
influenced by the activation of AKT. This would explain
the lower sensitivity of Ist-Mes-1 and MPP89 cell lines
with p-AKT.
Discussion
We have demonstrated in the Ist-Mes-2 MM cell line a
synergistic effect on the inhibition of cell growth
between the active small molecule inhibitor of EGFR,
gefitinib and rofecoxib, a drug that specifically targets
COX-2,. Interestingly, the other two cell lines sensitive
to treatment with single drugs, Ist-Mes-1 and MPP89,
did not display this synergistic effect. As already
described [30], COX-2 protein was appreciable in
MPP89, Ist-Mes-2 and Ist-Mes-1. We demonstrated that
EGFR phosphorylation was induced upon EGF treat-
ment in over-expressing COX-2 MM cell lines and that,
in these cell lines, EGFR inhibition with gefitinib and
COX-2 inhibition with rofecoxib lead to decreases in
proliferation. Gefitinib or rofecoxib treatment leads to
primarily cytotoxic effects in Ist-Mes-1, Ist-Mes-2 and
MPP89 cell lines. This is supported by the cytotoxicity
observed in our cell proliferation assays. This is the first
time that a cytotoxic effect has been observed on Ist-
Mes-1, Ist-Mes-2 and MPP89 cell lines treated with gefi-
tinib or rofecoxib. Previously, a study reported that gefi-
tinib treatment leads primarily to cytostatic rather
cytotoxic effect in MM cell lines [31]. As analyzed by
Western blotting, there appears to be no significant dif-
ferences in the amount of EGFR present in Ist-Mes-1
and Ist-Mes-2 cells, although the latter is much more
sensitive to the effects of gefitinib (Figure 3). Thus, in
MM cell lines, sensitivity to gefitinib inhibition is not
Figure 4 Curves of cell proliferation after the addition simultaneously of Rofecoxib and Gefitinib. Ist-Mes-1, Ist-Mes-2 and MPP89 were
treated with four different associations: 25 μM gefitinib+4 μM rofecoxib, 25 μM gefitinib+12 μMrofecoxib, 25 μM gefitinib+36 μMrofecoxib and
12 μM rofecoxib+12, 5 μM gefitinib. The survival of cells after treatment with drugs alone and in combination was compared to control
performed with DMSO at the same final concentration of that present in medium with drugs. Values were reported as means ± SD of three
independent experiments, and asterisks indicate significant difference (P < 0.05) of the treatment with two drugs vs single drug calculated by
Student’s t-test.
Table 1 Effect of gefitinib and rofecoxib combination in
MM cell lines according to the Chou and Talalay method
Cell Lines Schedule FA CI Effect
Ist-Mes-2 12 μM R+12.5 μM G 0.59 0.74 moderately synergistic
12 μM R+25 μM G 0.78 0.55 Synergistic
25 μM G+4 μM R 0.75 0.48 Synergistic
25 μM G+36 μM R 0.81 0.8 moderately synergistic
Ist-Mes-1 12 μM R+12.5 μM G 0.27 > 1.1 Antagonistic
12 μM R+25 μM G 0.20 > 1.1 Antagonistic
25 μM G+4 μM R 0.35 > 1.1 Antagonistic
25 μM G+36 μM R 0.17 > 1.1 Antagonistic
MPP89 12 μM R+12.5 μM G 0.22 > 1.1 Antagonistic
12 μM R+25 μM G 0.16 > 1.1 Antagonistic
25 μM G+4 μM R 0.60 > 1.1 Antagonistic
25 μM G+36 μM R 0.45 > 1.1 Antagonistic
Note: G indicates gefitinib, R indicates rofecoxib, FA denotes the fraction of
growth affect of drug-treated cells compared with control cells and CI
denotes the combination index.
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strictly related to the amount of EGFR. In addition, in
this study, to further substantiate the effect of gefitinib
on the EGFR down-regulation pathway, we showed the
inhibitory action of gefitinib on phosphorylation of the
tyrosine kinase domain of the EGFR in MPP89, Ist-Mes-
1 and, Ist-Mes-2 after treatment with EGF. In this con-
text the increase of p-AKT was reversed by gefitinib in
Ist-Mes-1 and MPP89, whereas no change of p-AKT in
Ist-Mes-2 was observed, because levels of activated AKT
were non-detectable. Gefitinib inhibition did not affect
the basal p-AKT status in Ist-Mes-1 and MPP89. These
data strongly confirm that EGF produced an increase of
p-AKT in the less sensitive gefitinib cell lines. In accor-
dance with these observations, the Ist-Mes-2 cell line,
sensitive to gefitinib, was the only cell line in which acti-
vation of AKT failed in the presence of EGF. Indeed, it
has been previously reported that persistent activity of
the PI3K/Akt and/or Ras/Erk pathways is associated
with gefitinib resistance of NSCLC cell lines [32]. PI3K/
Akt signalling pathway is negatively regulated by the
tumour suppressor gene phosphatase and tensin homo-
logue (PTEN). Over-expression of PTEN engenders
apoptosis in MM by AKT hypophosphorylation [33]. In
light of these facts it is possible to suppose that over-
expression of PTEN could be the basis of hypopho-
sphorylated Akt in the Ist-Mes-2 cell line. Further inves-
tigations are required to better clarify this mechanism.
Interestingly, reduction of p-AKT was observed in Ist-
Mes-1 and MPP89 treated with rofecoxib, suggesting
this pathway is responsible for a reduction of cancer cell
survival in these cell lines. In MPP89 and Ist-Mes-1
treatment with gefitinib and rofecoxib in combination
was not effective. In these cell lines the effect of rofe-
coxib on the phosphorylation of AKT was counteracted
by the addition of gefitinib. Only in Ist-Mes-2, the cell
line where p-AKT was not detectable, did the combina-
tion of rofecoxib and gefitinib result in a synergistic
effect. In order to obtain a better understanding of the
growth-inhibitory effect of rofecoxib and gefitinib, we
analyzed the expression of two cell cycle inhibitors, p21
and p27, in response to the in vitro treatment of cells
with single drugs or in combination. It is well documen-
ted that inhibition of the EGFR dependent pathway
induces a perturbation of cell cycle progression and
notably G1 arrest [34]. p21 and p27 are able to arrest
the growth of cells in the G1 phase of the cell cycle
[35]. The growth inhibitory effect induced by gefitinib in
Ist-Mes-2 increased expression of both p27 and p21. On
the contrary, no variation in levels of p21 and p27 was
observed in Ist-Mes-1 and MPP89. Indeed, p21 is criti-
cal for the activity of NSAID drugs and has been shown
to play a role in MM progression [36]. Rofecoxib, alone
and in combination with gefitinib, increased the expres-
sion of p21 and p27 only in Ist-Mes-2. Median effect
analysis using the CI method of Chou and Talalay [29]
confirmed a synergistic interaction between rofecoxib
and gefitinib in Ist-Mes-2. In contrast, the combination
of rofecoxib and gefitinib was not effective (antagonistic
interaction) in Ist-Mes-1 and MPP89. These data, when
considered together, indicate that gefitinib and rofecoxib
alone and in combination are effective only in Ist-Mes-
2, the cell line in which p27 and p21 are modulated and
in which the active form of AKT was un-detectable.
These results suggest that the differences in the suscept-
ibility to drugs could be due to the differences in the
signalling pathways affected, in addition to the responses
that may depend on cell type. Further investigations will
be undertaken to identify the mechanisms that underlie
these differences in sensitivity of MM cell lines to single
agents and their combinations, to identify new proteins
Figure 5 Effect of gefitinib and rofecoxib on p21, p27 and p-AKT. Ist-Mes-1, Ist-Mes-2 and MPP89 cell lines treated with gefitinib 25 μM ,
rofecoxib 4 μM and the combination gefitinib 25 μM +rofecoxib 4 μM for 48 hours were used to evaluate the effect of treatment on p21, p27,
p-AKT and AKT in western blot. Actin was used as loading control. An increase in the amount of p27 and p21 in Ist-Mes-2 cells but no
significant change in Ist-Mes-1 and MPP89 was reported. Phosphorylated AKT (p-AKT) was significantly reduced in Ist-Mes-1 and MPP89 by
treatment with rofecoxib. No detectable p-AKT was found in Ist-Mes-2 cells.
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involved in drug resistance. These proteins could subse-
quently be used as prognostic factors for drug resis-
tance, thereby enabling prediction of response before
starting treatment, in order to achieve a “tailored”
therapy.
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